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Tuberculosis	 (TB),	 a	major	 global	 public	 health	 concern,	 is	 known	 as	 a	 disease	 of	 the	 poor.	
However,	 evidence	on	 the	economic	burden	of	 TB	 is	 limited,	 and	 so	 is	 the	 literature	on	 the	
impact	of	poverty	alleviation	strategies,	such	as	social	protection	(SP),	on	financial	protection	
for	 TB	 patients.	 This	 PhD	 aimed	 to	 contribute	 to	 the	 body	 of	 knowledge	 on	 the	 costs	 and	
affordability	of	TB	care,	and	on	the	potential	mitigation	effect	of	SP	on	TB	patient	costs.	
	
Conceptual	 analyses	 and	 empirical	 data	 I	 collected	 as	 part	 of	 a	 nationally	 representative	 TB	
patient	cost	survey	in	Ghana	were	used	to	address	these	objectives:	
 








































































































































































































































































































drivers	 of	 TB	 (5).	 Poverty	 has	 been	 found	 to	 increase	 the	 risk	 of	 acquiring	 TB	 infection	 and	
developing	 the	 disease	 through	 more	 proximal	 risk	 factors	 such	 as	 malnutrition	 and	
overcrowded	living	conditions	(6-8).	
	
The	 poverty	 preference	 also	 affects	 access	 to	 care,	 particularly	 in	 low-	 and	 middle-income	
countries	(LMICs),	where	health	care	financing	is	largely	characterised	by	out-of-pocket	(OOP)	




available	 income	making	 them	more	 vulnerable	 and	 driving	 them	 further	 into	 poverty.	 This	
means	that	TB	patients	may	struggle	to	adhere	to	treatment	and	fail	to	complete	it	(11),	thus	











The	End	TB	Strategy	 therefore	 includes	a	 target	of	preventing	any	TB	patient	 from	 incurring	
catastrophic	costs	due	to	TB	by	2025,	defined	as	total	TB-related	(i.e.	non-medical	direct	costs	
of	 illness	and	 income	 losses)	exceeding	20%	of	pre-illness	annual	household	 income	 (14).	To	
monitor	progress	towards	this	milestone,	the	WHO	Global	TB	Programme	convened	a	task	force	











WHO	 refined	 and	 expanded	 the	 methodology,	 and	 developed	 a	 handbook	 in	 2017	 (16).	








underway	 in	 further	 9	 countries.	 Results	 from	 12	 of	 the	 completed	 surveys	 show	 that	 the	
proportion	of	TB	patients	and	their	households	experiencing	catastrophic	costs	ranged	from	27%	










suffered	 from	 small	 sample	 sizes	 or	 focussed	 on	 specific	 sub-populations,	 and	 employed	





While	Universal	Health	Coverage	 (UHC),	defined	as	affordable	access	 to	effective	care	 for	all	
(20),	is	critical	to	ensure	access	to	quality	TB	diagnosis	and	treatment	without	facing	financial	
hardship,	 interventions	 designed	 to	 defray	 or	 mitigate	 non-medical	 costs	 and	 income	 loss	
(beyond	medical	expenses)	are	equally	key	(21).	
	
Aligned	 with	 the	 Sustainable	 Development	 Goals	 (SDGs)	 and	 appreciating	 that	 TB	










and	 thereby	 seek	 to	 reduce	 income	 inequalities,	 alleviate	 poverty	 and	 improve	 health	 and	
development	outcomes.	Common	to	many	such	schemes	are	“conditions”	where	recipients	of	
transfers	are	required	to	undertake	activities	(such	as	infant	vaccination)	seen	as	beneficial	for	
themselves	 and	 the	 whole	 country,	 usually	 focused	 on	 health	 and	 education	 (in	 this	 case,	
transfers	are	called	conditional	or	targeted)	(23).		
	
















































































































monetary	 poverty,	 increase	 school	 attendance,	 improve	 the	 use	 of	 health	 services,	 dietary	
diversity	 and	 anthropometric	 measures,	 and,	 finally,	 can	 stimulate	 household	 savings	 (29).	
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The	 body	 of	 evidence	 for	 the	 impact	 of	 social	 protection	 on	 TB	 care,	 and	 particularly	 on	
treatment	outcomes,	has	recently	grown.	One	systematic	review	and	meta-analysis	concludes	
that	patients	in	LMICs	who	receive	cash	transfers	during	treatment	for	active	pulmonary	TB	are	
more	 likely	 to	 have	 a	 positive	 clinical	 outcome	 (35).	 Another	 review	 found	 an	 association	
between	social	protection	and	TB	treatment	success,	with	cure	of	patients,	and	with	a	reduction	
in	the	risk	of	defaulting	treatment	(36).	Findings	from	two	recent	studies	in	Brazil	suggest	that	
TB	 treatment	 outcomes	 improved	 among	 beneficiaries	 of	 a	 governmental	 cash	 transfer	






hardship	 in	response	to	TB	 is	 limited	(Research	gap	3).	Evidence	from	a	trial	among	MDR-TB	
patients	 in	 Peru	 demonstrates	 the	 effectiveness	 of	 a	 non-governmental	 cash	 transfer	
intervention	 in	 reducing	 the	 likelihood	 of	 incurring	 catastrophic	 costs	 (40).	 A	 cross-sectional	
study	 in	Rio	de	Janeiro,	Brazil,	shows	that	households	affected	by	MDR-TB	that	uptake	social	
protection	are	less	likely	to	experience	financial	hardship	(41).	Finally,	an	economic	modelling	




Author/Year	 Country	 Study	design	 	
Implementation	modela	 	 Impact	findingsb	





	 ●	 	 	 	 	 	 +/-	 	 	
Ciobanu/2014	(43)	 Moldova	 Retrospective	cohort	study	 	 ●	 	 	 	 	 	 ++	 	 	
Sripad	/2014	(44)	 Ecuador	 Cohort	study	 	 	 	 ●	 	 	 	 ++	 	 	





	 ●	 	 	 	 	 	 	 	 ++	





	 ●	 	 	 	 ++	 	 +	 	 	
Torrens/2016	(48)	 Brazil	 Retrospective	cohort	study	 	 	 	 ●	 	 	 	 ++	 	 	
Nery/2017	(49)	 Brazil	 Ecological	analysis	 	 	 	 ●	 	 ++	 	 	 	 	
Rudgard/2017	(34)	 Multi-country	 Economic	modelling	 	 ●	 	 ●	 	 	 	 	 	 +	
Durovni/2017	(50)	 Brazil	 Retrospective	cohort	study	 	 	 	 ●	 	 	 	 ++	 	 	
Rudgard/2018	(41)	 Brazil	 Cross-sectional	study	 	 	 	 ●	 	 	 	 	 	 +	
Carter/2018	(33)	 Brazil	 Quasi-experimental	study	 	 	 	 ●	 	 	 	 ++	 	 	
Boccia/2018	(51)	 Brazil	 Mathematical	Modelling	 	 	 	 ●	 	 +	 	 	 	 	
Carter/2018	(33)	 Multi-country	 Ecological	analysis	 	 	 	 ●	 	 ++	 	 	 	 	
Reis-Santos/2019	(37)	 Brazil	 Cohort	study	 	 	 	 ●	 	 	 	 +	 	 	
Klein/2019	(39)	 Argentina	 Cohort	study	 	 	 	 ●	 	 	 	 ++	 	 	
 18	
Oliosi/2019	(38)	 Brazil	 Cohort	study	 	 	 	 ●	 	 	 	 +	 	 	
	














variation	 of	 individuals’	 health	 care	 expenditures	 by	 pooling	 costs	 over	 time	 through	
prepayment	and	over	people	by	risk	pooling”	(53).	Insurance	can	be	mandatory	or	voluntary;	
national	insurance	(NHI,	or	social	health	insurance,	SHI)	is	generally	mandatory	covering	specific	
sections	 of	 the	 population	 (e.g.,	 public/formal	 sector)	 and	 has	 a	 single	 risk	 pool;	 voluntary	






improve	 financial	 protection	 by	 reducing	 out-of-pocket	 expenditures	 among	 the	 general	







on	 the	 integration	 (or	 potential	 for)	 of	 TB	 services	 into	 the	 service	 delivery	 package	 of	 NHI	
programmes.	Case	 studies	demonstrate	 that	 the	 inclusion	of	 TB	 services	 in	 SHI	 can	enhance	


















1.2 Rationale for this PhD 
	
In	light	of	the	existing	knowledge	and	research	gaps	listed	above,	the	importance	of	this	thesis	
is	 threefold.	First,	while	work	has	been	done	 in	assessing	costs	 for	TB	patients,	 there	remain	
critical	gaps	as	TB-related	costs	are	still	under	studied.	The	End	TB	Strategy	target	of	zero	TB-
































































































































































































illustrate	 the	 current	 methodological	 limitations	 of	 TB	 patient	 cost	 surveys	 to	 detect	 an	
association	between	costs	incurred	by	TB	patients	and	treatment	outcomes	(Research	paper	5).		
	





















































































































































































































































which	aim	 to	mitigate	economic	hardship	on	TB	patients	and	 their	households	due	 to	direct	
medical	and	non-medical	expenditures,	as	well	as	 lost	 income.	The	strategy	 includes	a	target	
that	no	families	should	face	catastrophic	total	costs	due	to	TB.	The	indicator	linked	to	this	target	
aims	 to	 capture	 the	 total	 economic	 burden	 linked	 to	 TB	 care,	 and	 thus	 differs	 from	 the	
“catastrophic	 expenditure	 on	 health”	 indicator,	 a	 key	 component	 of	 the	 UHC	 monitoring	
framework,	aligned	with	the	Sustainable	Development	Goals.	
	





























Aligned	 with	 the	 Sustainable	 Development	 Goals	 (SDGs),	 the	 World	 Health	 Organization´s	
(WHO’s)	 End	 TB	 Strategy	 has	 an	 increased	 focus	 on	 poverty	 alleviation	 strategies	 and	 social	
protection	 initiatives	that	cover	costs	beyond	medical	expenses,	 including	 income	security.	 It	
also	includes	as	a	target	that	no	TB-affected	families	should	suffer	from	catastrophic	total	costs	
due	 to	 the	 disease	 (10,	 11).	 To	 monitor	 progress	 towards	 this	 target,	 the	 WHO	 Global	 TB	
Programme	convened	a	 task	 force	of	experts	 in	2015	 to	develop	a	 field-testing	protocol	and	
survey	instrument	for	nationally	representative,	health	facility-based	surveys	of	costs	faced	by	
TB	patients	and	their	households	(“TB	patient	cost	surveys”),	building	upon	the	Tool	to	Estimate	
























































The	 WHO	 and	 the	 World	 Bank	 track	 financial	 protection	 through	 two	 indicators:	 high	 (or	
catastrophic)	health	spending	and	impoverishment	(6).	Catastrophic	health	spending	quantifies	
the	 proportion	 of	 the	 population	 whose	 resources	 would	 be	 catastrophically	 reduced	 by	
spending	 on	 health	 care	 (16).	When	 health	 care	 expenditures	 exceed	 a	 given	 proportion	 of	
available	 income	 (or	 expenditure	 capacity),	 they	 are	 considered	 “catastrophic”.	 The	













When	 measuring	 catastrophic	 health	 spending,	 there	 are	 two	 key	 variables	 underlying	 this	
approach:	1)	total	household	out-of-pocket	payments	for	health	care	(numerator,	see	Sections	






































these	 individuals	 (e.g.,	 the	mean	 for	 the	 lower	 quintiles	 based	 on	 national	 statistics	 or	 the	
minimum	civil	servant	wage).	
	
The	 output-based	 approach	 considers	 reported	 changes	 in	 income/production	 (21).	 This	































































































































to	 the	 end	 of	 anti-tuberculosis	 treatment.	 The	 denominator	 is	 further	 defined	 as	 annual	










The	 choice	 of	 the	 threshold	 is	 so	 far	 arbitrary.	 Various	 thresholds	 have	 been	 used	 in	 the	








TB	 Programmes	 (NTPs)	 that	 implement	 TB	 patient	 cost	 surveys	 whose	 results	 are	 annually	
reported	 to	 the	 WHO	 (1,	 38).	 Countries	 that	 conduct	 national	 TB	 patient	 cost	 surveys	 are	
encouraged	to	undertake	sensitivity	analyses	whereby	the	20%	threshold	is	altered	so	that	the	











TB	patients	with	 catastrophic	 costs	 divided	by	 the	number	 of	 all	 TB	 patients	 treated	 at	NTP	
facilities.	This	means	that	the	sampling	frame	is	notified	patients	on	treatment	rather	than	all	
people	with	 TB	 in	 the	 community,	 or	 households	 in	 a	 country.	 This	 is	 selected	 for	 practical	





















































2017,	 which	 provides	 comprehensive	 guidance	 for	 conducting	 facility-based	 cross-sectional	
surveys	to	assess	TB	patient	costs	(13).	This	would	benefit	from	periodic	methodological	updates	
based	on	multi-country	analyses	of	 survey	 findings	and	 strengthen	collaboration	with	health	
economists,	NTPs	and	policy	makers.	These	updates	include	methods	for	calculating	confidence	
intervals	 for	 key	 survey	 indicators	 adjusted	 for	 the	 sampling	 design,	 a	 regression-based	





going	 forward,	 including	 descriptive	 analyses	 of	 costs	 that	 unpack	 direct	 medical	 and	 non-
medical	 costs,	 and	 indirect	 costs,	 as	 they	 can	 provide	 valuable	 information	 to	 identify	 entry	
points	for	appropriate	polices	and	interventions	to	minimise	these	costs;	the	use	of	both	the	
human	 capital	 and	 the	 output-based	 approach	 to	 value	 indirect	 costs	 for	 comparison	 and	
correlation;	and	measuring	and	comparing	income	and	consumption	expenditure	to	compute	
financial	 protection	 measures.	 Approaches	 and	 metrics	 in	 addition	 to	 the	 standard	 End	 TB	
Strategy	 framework	 methodology	 include	 measuring	 impoverishment,	 computing	 the	





using	 a	measure	 at	 one	 point	 in	 time.	 It	 therefore	 fails	 to	 capture	 the	 long-term	 economic	
consequences	of	the	disease	for	the	household,	including	the	impact	on	reduced	labour	supply	
and	productivity,	and	household	resilience.	Coping	mechanisms	were	originally	explored	as	part	
of	 the	 development	 of	 the	 TB	 indicator	 as	 they	 were	 deemed	 to	 be	 potentially	 less	 labour	





including	 for	 long-term	 follow-up	 after	 anti-tuberculosis	 treatment,	 are	 now	 ongoing.	 These	
studies	will	be	helpful	 for	 the	validation	and	 interpretation	of	cross-sectional	TB	patient	cost	
 40	












In	 this	 paper,	 we	 have	 described	 economic	 burden	 and	 affordability	 concepts	 and	
measurements	that	underlie	the	End	TB	Strategy	indicator	of	“zero	catastrophic	costs”	due	to	
TB,	and	have	highlighted	the	novel	elements	of	this	indicator	in	relation	to	approaches	used	in	
the	 UHC	 monitoring	 framework.	 Further	 findings	 from	 national	 TB	 patient	 surveys,	 multi-
country	 analyses	 and	 research	 using	 alternative	 approaches	 will	 be	 important	 in	 providing	





capture	 the	 total	 economic	 burden	 of	 TB	 on	 patients	 and	 families.	 This	 approach	 has	 the	
potential	to	inform	the	design	of	financing	and	implementation	of	both	health	care	and	social	































































































































to	 inform	 changes	 to	 health	 service	 delivery	 and	 financing	 towards	 patient-centred	 care	 to	
eliminate	TB	patient	costs,	as	well	as	to	enhance	social	protection	measures.	This	article	was	


































Although	 national	 TB	 patient	 cost	 surveys	 focus	 on	 diagnosed	 TB	 patients,	 they	 also	 aim	 to	





with	 inception	 during	 the	 diagnostic	 pathway	 will	 inevitably	 miss	 those	 that	 never	 seek	 or	
receive	any	care,	or	do	so	at	facilities	that	are	not	captured	in	the	study	design.	Prospectively	
















TB	 patient	 cost	 surveys	 provide	 important	 information	 on	 how	 health	 service	 delivery	 and	
financing	can	be	changed	towards	patient-centred	care	to	eliminate	TB	patient	costs,	as	well	as	
 48	
enhancing	 social	 protection	 measures	 (3).	 They	 are	 a	 powerful	 tool	 to	 draw	 focus	 towards	
eliminating	 the	 financial	 plight	 and	 barriers	 for	 presumptive	 and	 TB	 patients,	 through	
collaboration	with	relevant	stakeholders	within	and	across	the	health	sector.	
	
For	 example,	 addressing	 pre-diagnosis	 medical	 costs	 involves	 streamlining	 the	 TB	 patient	
pathway,	expanding	access	 to	 rapid	molecular	 testing	and	digital	X-rays,	 intensifying	 contact	
investigation	 and	 case	 finding	 (5),	 looking	 for	 synergies	with	 programmes	 on	 HIV,	 nutrition,	
diabetes.	
	
Ghana,	 the	 first	 country	 in	 Africa	 to	 conduct	 a	 national	 TB	 patient	 cost	 survey	 (6),	 recently	
developed	a	national	roadmap	to	eliminate	financial	catastrophe	for	TB	patients	through	a	broad	















































































to	 incur	unmanageable	costs	due	 to	seeking	and	staying	 in	care	 for	 the	 full	duration	of	anti-
tuberculosis	treatment	(1).	By	aggravating	household	vulnerability,	these	costs	can	prevent	or	
delay	 diagnosis,	 treatment	 and	 successful	 outcome,	 leading	 to	 increased	 TB	 transmission,	
morbidity	 and	mortality	 (2-4).	 The	new	World	Health	Organization	 (WHO)’s	 End	 TB	 Strategy	









































and	 patients	 under	 follow-up	 (Kyrgyz	 Republic).	 In	 contrast,	 sputum	 smear	 microscopy	 is	
provided	free	of	charge	in	all	countries.	In	countries	where	chest	radiographs	are	also	employed	
for	monitoring	progress	during	treatment,	 this	exposes	patients	 to	even	higher	costs	as	 they	










































low-income	 countries	without	 a	 national	 health	 insurance	 scheme	 (such	 as	 Zimbabwe).	 The	
same	holds	true	for	middle-income	countries	(Vietnam,	Dominican	Republic,	Indonesia,	Peru).	
However,	 those	 countries	 often	 have	 health	 insurance	 schemes	 covering	 the	 costs	 of	 chest	
radiographs.	Health	insurance	schemes	based	on	a	contributory	model	(such	as	in	Ghana)	are	





























































radiography	 costs	 in	 the	private	 sector	 can	 be	up	 to	 four	 times	higher	 than	 in	 public	 health	
facilities	(USD	2.5-8.0	versus	USD	1.5-2.0).	
	
Our	survey	 is	not	 representative	of	 the	global	 level,	nor	was	 it	 intended	to	be.	However,	we	







radiography	might	 potentially	 aggravate	 costs	 for	 patients	 and	 presumptive	 TB	 cases.	 chest	
radiography,	similar	to	sputum	smear	microscopy	and	Xpert	MTB/RIF	(Cepheid,	Sunnyvale,	CA,	
USA),	should	be	easily	accessible	and	free	of	charge	if	employed	for	TB	diagnosis	and	follow-up.	
A	 recently	 published	 WHO	 policy	 document	 on	 chest	 radiography	 aptly	 states	 that	 chest	
radiography	 should	 be	 free	 of	 charge	 and/or	 fully	 reimbursed	 by	 health	 insurance	 (9).	
Additionally,	practical	approaches	 to	mitigate	patient	costs	 should	also	be	provided	 to	NTPs.	
Harmonisation	within	 and	 across	 countries	 and	 donors	will	 be	 necessary.	 Another	 potential	
avenue	to	reducing	the	costs	for	patients	is	the	extension	of	social	protection	interventions	(such	
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households	 during	 care	 seeking	 and	 treatment;	 assesses	 affordability	 of	 TB	 care	 using	
catastrophic	 and	 impoverishment	 measures;	 and	 describes	 coping	 strategies	 used	 by	 TB-
affected	households	to	pay	for	TB	care.	
	
























inequity	 fuel	 the	TB	epidemic	 (3,	 4).	 Poverty	 increases	 the	 risk	of	 acquiring	TB	 infection	and	
developing	 the	 disease	 through	 more	 proximal	 risk	 factors	 such	 as	 malnutrition	 and	
 62	
overcrowded	 living	 conditions	 (5-7).	 Poverty	 also	 limits	 access	 to	 care	 for	 TB	 patients,	
particularly	 in	 low-	 and	 middle-income	 countries	 (LMICs),	 where	 health	 care	 financing	 is	
characterised	by	a	heavy	reliance	on	out-of-pocket	(OOP)	payments	and	the	limited	coverage	of	




costs	 reduce	 available	 income	 making	 the	 patient	 and	 their	 household	 more	 vulnerable	 to	
financial	hardship	(11).	Where	households	struggle	to	afford	care,	TB	patients	will	be	less	likely	









However,	 while	 there	 have	 been	 previous	 assessments	 of	 TB	 patient	 costs	 in	 LMICs	 (18)	
(including	in	Ghana,	(19)),	most	studies	did	not	report	costs	as	a	proportion	of	income,	nor	did	













Despite	 positive	 economic	 growth	 over	 the	 past	 two	 decades	 and	 consequent	 reduction	 in	




TB	 incidence	 in	 Ghana	 was	 estimated	 at	 about	 160	 per	 100,000	 population	 in	 2016	 (2).	 A	






In	 late	2016,	we	conducted	a	nationally	 representative	 survey	with	 random	cluster	 sampling	






facility	 within	 a	 sampled	 cluster,	 who	 had	 received	 at	 least	 two	 weeks	 of	 intensive	 or	
continuation	phase	treatment,	and	who	consented	to	the	study.		In	total,	734	individuals	were	







receiving	 care),	up	 to	 the	 time	of	 interview.	To	value	 time,	we	employed	 the	output-related	
approach,	by	which	the	value	of	time	is	defined	as	the	difference	in	household	annual	income	
pre	 and	 post-TB	 diagnosis	 (24).	 To	 minimise	 recall	 bias,	 data	 were	 collected	 only	 for	 the	
















for	 the	 “zero	 TB-affected	 families	 facing	 catastrophic	 costs	 due	 to	 TB”	 indicator,	 costs	were	








Income	 was	 measured	 as	 self-reported	 individual	 and	 household	 income	 where	 available	
(n=553).	 If	 missing,	 income	 estimates	 were	 based	 on	 self-reported	 household	 assets	 (e.g.	

































used	 in	 the	 healthcare	 literature	 (30-33).	 The	 catastrophic	 payment	 headcount	 was	 also	
computed	 using	 consumption	 expenditure	 instead	 of	 income	 as	 a	 robustness	 check	 (34),	
because	 in	 settings	 where	 employment	 is	 mainly	 outside	 the	 formal	 sector,	 consumption	
expenditure	is	often	believed	to	be	a	more	valid	measure	than	income	(35-37).	Finally,	we	also	

































		Female	 	202	32.3%)	 	24	(36.4%)	 	226	(32.7%)	
Age	in	years,	Median		[IQR]	 	41	[29-52]	 	43	[29-50]	 0.88	 	41	[29-52)	




			Continuation	 	415	(66.4%)	 	44	(66.7%)	 	459	(66.4%)	




		Negative	 	431	(69.0%)	 	32	(48.5%)	 	463	(67.0%)	
		Unknown	 	73	(11.7%)	 	26	(39.4%)	 	99	(14.3%)	




		Retreatment/Relapse	 	65	(10.4%)	 	11	(16.7%)	 	76	(11%)	
Diagnosis	delay	(weeks	),	Median	(SD)	 4	(16.2)	 6	(12.9)	 		 4	(15.9)	
		N	(%)	 80	(44.2%)	 10	(52.6%)	 0.48	 90	(45%)	




			Primary	school	 122	(19.6)	 8	(12.1)	 130	(18.9)	
			Secondary	school	/	High	school	 	350	(56.2)	 	42	(63.6)	 	392	(56.9)	
			University	and	higher	 	26	(4.2)	 	5	(7.6)	 	31	(4.5)	




Not	salaried	 269	(51.2)	 36	(61.0)	 305	(52.2)	
Not	employed	/	In	school	 186	(35.4)	 14	(23.7)	 200	(34.3)	




			Rural	 177	(28.5)	 19	(28.8)	 196	(28.5)	























median	 costs	 after	 diagnosis	 were	 almost	 three	 times	 greater	 for	 the	 MDR	 group	 (P-
value<0.0001)	(US$	1276	vs.	US$	481),	due	to	higher	levels	of	non-medical	costs	among	the	MDR	


































income	was	64.1%	 (443/691)	 (95%	 confidence	 interval:	 60.5%-67.6%)	 (catastrophic	 payment	
 68	





































Coping	strategies	 DS,	%	(N)	 MDR,	%	(N)	 All,	%	(N)	
Loan	 27.0	(169/625)	 30.3	(20/66)	 27.4	(189/691)	
Use	of	savings	 29.4	(184/625)	 16.7	(11/66)	 28.2	(195/691)	
Sale	of	assets	 10.7	(67/625)	 15.2	(10/66)	 11.1	(77/691)	


















level	 of	 costs	 incurred	decreased	by	 18.2%,	 leading	 to	 lower	 estimates	of	 catastrophic	 costs	




of	 households	 incurring	 catastrophic	 costs	 was	 fairly	 consistent	 (61.8%)	 and	 the	 difference	
between	 DS	 and	 MDR	 patients	 remained	 statistically	 insignificant	 (61.2%	 versus	 67.7%,	 P-
value=0.305).	
	
As	 the	 income	 threshold	 increases,	 the	 catastrophic	 payment	 headcount	 ratio	 decreases	
accordingly,	but	even	at	a	40%	threshold	of	annual	household	income	42.3%	of	patients	would	
be	 still	 considered	 to	 incur	 catastrophic	 costs	 (supplementary	 Figure	 1A).	 This	 ratio	 was	
significantly	different	for	DS	and	MDR	patients	(40.6%	versus	57.6%,	P-value=0.008).	
		








an	 additional	 14.2%	 pushed	 into	 poverty	 due	 to	 the	 disease,	 and	 half	 undertaking	 coping	
strategies	to	finance	costs.	The	increase	in	the	poverty	gap	means	that	not	only	is	the	number	
of	 TB-affected	 households	 in	Ghana	 that	 experience	 catastrophic	 health	 payments	 high,	 but	




Median	 costs	 that	 TB	 patients	 incurred	 in	 Ghana	 are	 higher	 than	 what	 was	 found	 in	 the	
systematic	review	by	Tanimura	et	al.	(US$	379),	and	in	a	previous	study	conducted	by	Mauch	et	
al.	in	two	regions	of	Ghana	in	2009	(US$	202)	(14,	19).	Although	it	is	hard	to	directly	compare	




The	 proportion	 of	 TB	 patients	 living	 below	 the	 poverty	 line	 is	 greater	 than	 in	 the	 general	
population	(45.6%	vs.	24.2%)	(38).	This	means	that	TB	patients	are	more	vulnerable	and	policies	
that	 can	 effectively	 defray	 costs	 incurred	 by	 TB	 patients	 are	 warranted.	 As	 direct	 medical	
expenditures	 only	 account	 for	 18.2%	 of	 total	 costs,	 universal	 health	 coverage	 is	 unlikely	 to	
impact	 on	 the	 number	 of	 families	 facing	 catastrophic	 costs.	 Income	 loss	 and	 food	 and/or	
nutritional	 supplements	 are	 the	 largest	 cost	 components.	 This	 calls	 for	 social	 protection	








their	 job	 as	 a	 result	 of	 TB,	 labour	 protection	 for	 TB	 patients	 needs	 to	 be	 endorsed	 and	
implemented	effectively.	
	
Costs	 incurred	 pre-diagnosis	 only	 account	 for	 7.0%	 of	 total	 costs.	 The	 difference	 in	 costs	
between	DS	and	MDR	lies	primarily	in	post-diagnosis	costs.	This	is	consistent	with	other	surveys	
that	followed	the	WHO	methodology	(40),	but	considerably	differs	from	the	findings	from	the	

















































the	 entire	 episode	 using	 two	 different	 approaches.	 While	 this	 assumes	 that	 every	 patient	
successfully	completes	treatment,	it	is	difficult	to	determine	how	patients	who	fail	and/or	re-

















costs,	 and	ensure	TB	 care	 is	 actually	 affordable	 for	 TB	patients.	 It	 is	 therefore	essential	 that	
countries	undertaking	TB	patient	cost	surveys	follow	up	on	the	survey	findings	by	conducting,	





































































































































Median	 IQR	 Median	 IQR	 Median	 IQR	
Costs	before	diagnosis	 31.6	 30.2-35.9	 32.8	 31.4-37.3	 31.7	 30.2-35.9	
Medical	costs	 26.7	 26.7-26.7	 27.7	 27.7-27.7	 26.7	 26.7-26.7	
Non-medical	costs	 	2.9	 2.9-2.9	 	2.9	 2.9-2.9	 2.9	 2.9-2.9	
Costs	after	diagnosis	 481.7	 220.1-1032.8	 1276.3	 442.7-2456.2	 519.3	 232.3-1161.2	
Medical	costs	 74	 55.8-77.0	 40.7	 8.3-101.3	 70.0	 55.8-77.5	
Non-medical	costs	 140.6	 31.0-427.6	 427.6	 112.1-1061.3	 149.3	 32.3-524.0	
Travel		 	18.3	 	8.1-49.2	 27.1	 8.1-131.2	 18.3	 8.1-51.3	
Accommodation	 0.0	 0.0-0.0	 0.0	 0.0-0.0	 0.0	 0.0-0.0	
Food/nutritional	
supplements	 68.4	 9.7-327.5	 227.9	 18.9-708.4	 78.2	 10.1-360.1	
Caregiver's	time	 0.0	 0.0-0.74	 0.0	 0.0-20.5	 0.0	 0.0-0.56	
Income	loss	 0.0	 0.0-195.2	 0.0	 0.0-216.9	 87.3	 0.0-506.0	








Median	 IQR	 Median	 IQR	 Median	 IQR	
Costs	before	diagnosis	 19.2	 17.9-27.6	 12	 10.4-17.2	 12.4	 10.5-19.1	
Medical	costs	 15.7	 15.7-15.7	 8.4	 8.4-8.4	 8.4	 8.4-8.4	
Non-medical	costs	 1.2	 1.2-1.2	 1.2	 1.2-1.2	 1.2	 1.2-1.2	
Costs	after	diagnosis	 404.6	 150.9-958.8	 1250.8	 431.9-2405.9	 454.1	 163.2-1083.5	
Medical	costs	 0.0	 0.0-14.4	 0.0	 0.0-86.7	 0.0	 0.0-20-6	
Non-medical	costs	 129.5	 19.3-484.0	 425.2	 109.6-1051.7	 139.7	 21.7-516.0	











Income	 53.1	(332/625)	 72.7	(48/66)	 55.0	(380/691)	
Consumption	












household	 characteristics	 (e.g.,	 the	 type	 of	 flooring	 material,	 availability	 of	 electricity,	 the	
number	of	 rooms	used	 for	 sleeping,	place	 for	 cooking,	 type	of	 cooking	 fuel),	 and	household	
possessions	 (e.g.	 household	 effects	 such	 as	 radio,	 colour	 television,	 mobile/non-mobile	
telephone,	refrigerator;	means	of	transport,	including	bicycle,	animal	drawn	cart,	car/truck,	boat	







This	method	may	be	useful	 in	countries	 like	Ghana	with	a	 large	 informal	sector	and	where	a	













doing	 so,	 this	 chapter	 addresses	 the	 third	 research	 gap	 identified	 by	 the	 thesis:	 the	 limited	
knowledge	on	determinants	of	TB	patient	costs	and	on	the	potential	impact	of	social	protection	
on	 TB	 patient	 costs.	 The	 paper	 was	 submitted	 to	 Social	 Science	 &	Medicine	 at	 the	 time	 of	
submission	of	the	thesis.	
	
























We	reported	 the	 level	of	direct	and	 indirect	costs,	 the	proportion	of	TB-affected	households	
experiencing	 catastrophic	 costs,	 and	 potential	 determinants	 of	 costs,	 stratified	 by	 insurance	
status.	Regression	models	were	used	to	determine	drivers	of	costs	and	affordability.	The	effect	


























(3),	 the	 World	 Health	 Organization’s	 (WHO’s)	 End	 TB	 Strategy	 calls	 for	 multi-sectoral	







Financial	barriers	are	a	key	 limitation	to	accessing	health	services	 in	 low-	and	middle-income	
countries	 (LMICs),	 where	 health	 sector	 financing	 is	 often	 characterised	 by	 out-of-pocket	
payments	 (user	 fees)	 for	 the	 individual	 and	 limited	 prepayment	mechanisms	 (e.g.,	 taxation,	
health	insurance)	(6).	Generally,	basic	TB	diagnosis	and	care	are	officially	offered	free	of	charge	
to	 presumptive	 TB	 cases	 and	 TB	 patients,	 often	 financed	 through	 special	 vertical	 funding	
mechanisms,	that	supplement	domestic	resources.	Yet,	the	TB	care	pathway	remains	long	and	

























































































Ghana	was	 the	 first	 country	 in	 sub-Saharan	 Africa	 to	 introduce	 a	 National	 Health	 Insurance	
Scheme	(NHIS)	in	2003.	NHIS	covers	both	formal	and	informal	sector	workers.	Currently,	about	
40%	of	Ghana’s	population	is	enrolled	with	a	valid	membership	card	(15).	Children	under	the	18	
years	 constituted	 the	 largest	 proportion	 (46.5%)	 of	 active	 NHIS	 members,	 followed	 by	 the	








































































18.2%	and	47.4%	of	 total	 costs	 respectively,	while	 income	 loss	 accounted	 for	 the	 remaining	




showed	 that	 the	 scheme	 has	 a	 protective	 effect	 against	 the	 financial	 burden	 of	 health	 care	
among	the	general	population	(15,	17).	One	study	found	that	NHIS	had	a	protective	(although	
non-significant)	 effect	 on	 the	 cost	 of	 malaria	 treatment	 incurred	 by	 patients	 (20).	 To	 our	




insurance	 as	 a	 key	 instrument	 for	 preventing	 TB-affected	 households	 from	 experiencing	
financial	hardship	 (21).	However,	evidence	on	this	potential	 remains	 limited,	thus	preventing	
the	swift	translation	of	these	recommendations	into	policy.	Given	the	high	coverage	of	NHIS	and	
















well	 as	 on	 TB-related	 costs	 incurred	 by	 them	 over	 the	 entire	 TB	 episode.	 These	 costs	
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income	 loss)	 and	 the	 proportion	 of	 TB-affected	 households	 experiencing	 catastrophic	 costs	
across	the	insured	and	the	uninsured.	We	also	compared	the	characteristics	of	the	insured	and	
uninsured	 on	 variables	 that	 are	 likely	 to	 be	 associated	 with	 cost.	 Potential	 determinants	




Consistent	 with	 the	 approach	 adopted	 by	 WHO	 for	 the	 ‘zero	 TB-affected	 families	 facing	
catastrophic	 costs	 due	 to	 TB’	 indicator,	 costs	 were	 defined	 as	 ‘catastrophic’	 if	 a	 household	














are	 often	 right	 skewed	 and	 left	 censored	 (zeros)	 and	 thus	 may	 violate	 the	 assumption	 of	
normality	 required	 for	 standard	 linear	 regression	 techniques	 (23).	A	 logarithmic	 transform	 is	






















































probability	of	being	enrolled	 in	 the	NHIS	given	a	 set	of	 covariates,	 regardless	of	whether	an	
individual	was	actually	enrolled	or	not.	We	then	weighted	participants	using	the	inverse	of	their	





























































































loss	 by	 just	 above	 US$	 200,	 and	 total	 costs	 by	 just	 above	 US$	 300.	 Larger	 households	 had	
increased	medical,	non-medical,	and	total	costs	compared	to	smaller	households.	Having	MDR-

































































Our	 study	 advances	 the	 literature	 on	 financial	 protection	 for	 TB	 patients	 by	 investigating	





























individuals	 who	 are	 insured	 benefit	 from	 a	 greater	 choice	 of	 providers,	 including	 private	
providers,	and	therefore	may	not	need	to	travel	as	far,	thus	incurring	less	transport	costs	(29).	
	
The	 lack	of	evidence	suggesting	 that	enrolment	 in	 the	NHIS	defrayed	medical	 costs,	possibly	
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explains	findings	from	the	survey	that	medical	expenditures	are	still	substantial	and	constitute	






































majority	 belong	 to	 the	 poorest	 segments	 of	 society,	 could	 benefit	 from	NHIS	 prior	 to	 being	
diagnosed	with	TB,	thus	reducing	diagnostic	delays	and	possibly	the	severity	of	the	disease.	
	
Mechanisms	 to	 refer	 indigent	 TB	 patients	 identified	 through	 NHIS	 to	 patient/social	 support	
should	 also	 be	 considered.	 Non-medical	 costs	 and	 income	 loss	 accounted	 for	 the	 largest	
proportion	of	total	costs.	Only	four	(0.6%)	of	patients	in	our	study	were	enrolled	in	the	Livelihood	
Empowerment	Against	Poverty	(LEAP),	the	national	cash	transfer	programme	to	extremely	poor	
















approach	 to	 control	 for	 confounding,	 which	 requires	 fewer	 assumptions	 about	 the	 data	
compared	 to	 a	 traditional	 parametric	methodology	 (38,	 39),	 and	 is	more	 robust	 to	 estimate	
treatment	effects	using	observational	data	(24).	Specifying	the	appropriate	model	for	examining	





to	 interventions	and	policy	 changes	 that	help	 reduce	or	mitigate	 these	 costs;	 therefore,	 it	 is	











Using	Ghana	as	 a	 case	 study,	we	 showed	 that	even	 in	 countries	with	well-established	 state-
supported	health	insurance	schemes	and	free	TB	care	policies,	TB	patients	are	at	risk	of	incurring	
high	costs	when	seeking	and	accessing	TB	care,	including	medical	costs	which	are	meant	to	be	






























































































































































and	 argue	 that	 TB	 treatment	 outcomes	 as	 routinely	measured	 and	 reported	 by	 national	 TB	
programmes	for	surveillance	purposes,	are	not	a	good	measure	of	treatment	“success”.	While	
patients	may	be	considered	to	have	successfully	completed	TB	treatment,	the	impact	of	TB	is	














While	progress	 in	 tuberculosis	 (TB)	 control	 is	undeniable,	 for	many	countries	ending	 this	old	






















patients	 (4).	 However,	 as	 part	 of	 a	 TB	 patient	 cost	 survey,	 investigators	 may	 also	 seek	 to	






they	died,	were	 lost	 to	 follow	up	or	had	treatment	 failure.	 In	 the	present	paper,	we	refer	 to	
treatment	 outcomes	 as	 routinely	 measured	 and	 reported	 by	 national	 TB	 programmes	 for	
surveillance	purposes.	
	




























household).	 The	 End	 TB	 strategy’s	 vision	 of	 zero	 suffering	 and	 financial	 hardship	 due	 to	 TB	












the	 proportion	 of	 patients	 experiencing	 catastrophic	 costs	 (the	 primary	 outcome	 of	 these	
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We	 also	 considered	 a	 prevalence	 of	 catastrophic	 costs	 at	 25%,	 50%	 and	 75%,	 proportions	










exceeds	 10%	 (1).	 The	 prevalence	 of	 catastrophic	 costs	 varies	 greatly	 between	 different	
countries,	and	is	as	low	as	27%	in	Kenya	and	as	high	as	83%	in	Timor-Leste	(1).	Therefore,	the	
sample	 size	 of	 most	 TB	 patient	 cost	 surveys	 is	 too	 small	 to	 detect	 an	 association	 between	
catastrophic	 costs	 and	 TB	 outcomes	 (assuming	 a	 relative	 risk	 of	 1.5).	 To	 illustrate	 this,	 we	
calculated	 the	 sample	 size	 that	 would	 be	 required	 to	 detect	 a	 risk	 ratio	 of	 1.5	 between	
individuals	 facing	 catastrophic	 costs	 and	 those	who	 do	 not,	 based	 on	 data	 from	 completed	
national	 TB	 patients	 cost	 surveys,	 and	 using	 the	 prevalence	 of	 adverse	 outcomes	 in	 these	
countries.	Finally,	we	compared	the	estimated	sample	size	to	the	actual	sample	size	of	these	

















(Annex	 B,	 Figure	 B1),	 we	 found	 no	 evidence	 of	 a	 difference	 in	 adverse	 treatment	 outcome	






Another	major	 limitation	 is	 the	 lack	 of	 heterogeneity	 among	 TB	 patients	 participating	 in	 TB	
patient	 cost	 surveys	which	makes	 it	difficult	 to	assess	a	potential	 impact	of	patient	 costs	on	
treatment	outcomes.	Most	TB	patients	belong	to	the	poorest	segments	of	society	in	the	world’s	
poorest	 settings.	 For	 example,	 the	proportion	of	 TB	patients	 included	 in	 the	TB	patient	 cost	




risk	 factors	 is	 very	 limited	 in	 resource	 constrained	 settings	 (13),	 and	 this	 is	 unlikely	 to	






Besides,	 the	question	of	what	would	be	 a	meaningful	 and	 relevant	 effect	 size	has	 remained	
unanswered:	what	effect	size	would	make	policy	makers	adopt	an	intervention	to	reduce	the	
burden	of	catastrophic	costs	with	the	aim	to	improve	TB	treatment	outcomes?	This	leads	on	to	
another	 (maybe	more	 important)	 question:	 does	 a	 reduction	 in	 catastrophic	 costs	 need	 any	





To	 further	explore	 the	challenges	 in	drawing	conclusions	about	 the	strength	of	 the	evidence	
supporting	 an	 association	 between	 catastrophic	 costs	 and	 adverse	 treatment	 outcomes,	we	
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patient	 and	 their	 household	prior	 to	 starting	 TB	 treatment,	 rather	 than	 the	direct	 impact	 of	
experiencing	catastrophic	costs	(Figure	11).	
	












traditional	 surveillance	 outcomes,	 that	 tend	 to	 overlook	 the	 impact	 of	 the	 disease	 on	 the	




While	 patients	 may	 be	 considered	 to	 have	 successfully	 completed	 TB	 treatment,	 the	
consequences	 of	 the	 disease	 are	 often	 far	 reaching	 for	many	 of	 them,	 and	 include	medical	
conditions	 (e.g.	 chronic	 lung	 disease),	 mental	 health	 implications,	 socio-economic	
consequences,	stigma	and	disabilities	(17).	Aligned	with	the	End	TB	Strategy’s	focus	on	patient-
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centred	 care	 and	 the	 SDGs,	 this	 calls	 for	 more	 meaningful	 outcomes	 that	 would	 take	 into	







current	 scope	 and	 methodology	 have	 clear	 limitations.	 Future	 research	 should	 expand	 the	










ad-hoc	 research	 in	 these	 surveys	 may	 be	 tempting,	 as	 treatment	 outcome	 data	 are	 easily	
available	in	TB	treatment	registers.	However,	there	are	two	major	arguments	we	should	bear	in	
mind.	First,	we	should	ponder	the	rationale	for	performing	such	analysis	given	all	the	limitations	





more	 holistic,	 patient-centred	 approach	 is	 warranted,	 together	with	 a	more	 comprehensive	
research	agenda.	This	should	naturally	look	at	broader	outcomes,	that	capture	the	health	(e.g.	
morbidity,	 health-related	 quality	 of	 life),	 wellbeing	 and	 socio-economic	 (e.g.	 educational	















































































































thesis.	 These	 are	 summarised	 in	 Table	 15,	 together	 with	 the	methods	 employed,	 the	main	
findings	and	the	areas	for	further	research.	
		
Focusing	 on	 the	 four	 knowledge	 gaps	 addressed	 by	 this	 thesis	 and	 its	 objectives,	 this	 final	
chapter	briefly	recalls	the	state	of	the	evidence	before	the	PhD,	and	summarises	how	research	
completed	as	part	of	it	advances	that	area	of	research.	It	also	discusses	the	policy	implications	























































































































































































2) The	 disruption	 caused	 by	 costs	 related	 to	 TB	 diagnosis	 and	 care	 has	 much	 wider	















This	 chapter	 provides	 the	 conceptual	 framework	 of	 the	 PhD.	 It	 reviews	 and	 defines	 core	
concepts	 of	 relevance	 to	 this	 thesis:	 costs	 and	 their	measurement,	 and	 affordability.	 It	 also	




methodology,	 this	 paper	 also	 aimed	 to	 provide	 the	 TB	 community	 with	 a	 comprehensive	
description	of	the	concepts	and	measurements	that	underlie	the	End	TB	Strategy	indicator	of	





































Finally,	 this	 thesis	 expanded	 on	 the	 WHO	 methodology	 by	 employing	 a	 prediction	 based	
approach	to	estimate	missing	costs,	and	by	using	household	consumption	expenditure	instead	
of	 income	 to	 compute	 the	 catastrophic	 payment	 headcount	 metric.	 The	 regression-based	
approach	led	to	lower	levels	of	costs	incurred,	leading	in	turn	to	lower	estimates	of	catastrophic	
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sample	 sizes	 or	 focussed	 on	 specific	 sub-populations,	 and	 employed	 heterogeneous	
methodologies	(1,	2).	Further,	most	studies	did	not	report	costs	as	a	proportion	of	income,	nor	
did	they	measure	affordability	of	TB	care	(3).	This	PhD	contributed	important	evidence	on	TB	
patient	 costs	 and	 affordability	 on	 a	 nationally	 representative	 population	 sample,	 using	 and	
expanding	the	WHO	methodology.	
	





Given	 the	 catastrophic	 costs	 incurred	 by	 TB	 patients	 identified	 in	 Chapter	 4,	 this	 PhD	 also	
examined	 the	 drivers	 of	 these	 costs,	 and	 the	 effectiveness	 of	 social	 protection	 strategies	 in	
mitigating	 these	 costs.	 This	 thesis	 found	 that	 the	 poorest	 patients,	 those	 living	 in	 an	 urban	





survey.	 Using	 Ghana	 as	 a	 case	 study,	 this	 PhD	 showed	 that	 even	 in	 countries	 with	 well-
established	state-supported	health	insurance	schemes	and	free	TB	care	policies,	TB	patients	are	







instrument	 for	 preventing	 TB-affected	 households	 from	 experiencing	 financial	 hardship	 (6),	
evidence	 on	 this	 potential	 is	 growing	 but	 remains	 limited	 (7,	 8).	 This	 knowledge	 gap	 has	
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prevented	 the	 swift	 translation	 of	 these	 new	 policy	 recommendations	 into	 effective	
interventions.	 The	 assessment	 of	 the	 effectiveness	 of	 NHIS	 in	 defraying	 TB	 patient	 costs	












endorsed	 by	WHO,	 and	 also	 to	 provide	 evidence	 on	 the	 clinical	 implications	 of	 catastrophic	
costs.	
	





outcomes.	 Therefore,	 this	 thesis	 shows	 that	 most	 completed	 TB	 patient	 cost	 surveys	 are	





costs	 and	 treatment	 outcomes	 did	 exist,	 focusing	 on	 such	 a	 relationship	 may	 actually	 be	
misleading	 as	 the	 consequences	 of	 TB	 extend	 well	 beyond	 treatment	 completion,	 and	 are	
broader	than	surveillance	outcomes.	It	concludes	that	the	TB	community	should	look	at	broader,	
















































This	 thesis	 therefore	 sets	 an	 example	 of	 the	 potential	 of	 TB	 patient	 cost	 surveys	 to	 lead	 to	
interventions	and	policy	changes	that	help	reduce	or	mitigate	costs	incurred	by	TB	patients;	it	
















cost	 survey	 in	Ghana,	which	 inevitably	 focuses	on	 the	economic	consequences	of	TB	using	a	
measure	at	one	point	in	time.	It	therefore	fails	to	capture	the	long-term	economic	consequences	
of	 the	disease	 for	 the	 individual	and	 the	household,	 including	 the	 impact	on	 reduced	 labour	


































Equally,	dedicated	 longitudinal	 studies	with	an	adequate	sample	size	should	be	employed	 to	
assess	the	potential	impact	of	TB	patient	costs	on	TB	treatment	outcomes.	A	first	step	would	be	











The	methods	employed	 in	 this	PhD	and	 its	 findings	may	 inform	 future	 revisions	of	 the	WHO	




The	computation	of	all	 the	metrics	of	affordability	based	on	 the	concept	of	 catastrophic	TB-
related	 expenditure	 (i.e.,	 catastrophic	 payment	 gap	 in	 addition	 to	 the	 catastrophic	 payment	
headcount	on	which	the	TB	indicator	is	based)	and	the	concept	of	impoverishment	due	to	TB-
related	spending	(i.e.,	incidence	of	impoverishment	and	poverty	gap)	provided	a	comprehensive	
snapshot	 of	 the	 affordability	 of	 TB	 care	 in	 Ghana.	 All	 these	 indicators	 should	 be	 routinely	
computed	and	monitored	as	part	of	the	analysis	and	reporting	of	TB	patient	cost	surveys.	
	
This	 PhD	 also	 used	 annual	 household	 consumption	 expenditure	 instead	 of	 income	 as	 a	





7.4.5 Concluding remarks 
	










































































October	 2015	 in	 New	 York	 City,	 and	 reflects	 the	 renewed	 interest	 in	 measuring	 the	
socioeconomic	impact	of	disease	on	patients	and	their	household.	This	paper	was	published	in	





























































burden	 falling	on	the	poorest	 in	society	and	the	most	vulnerable	communities.	 	The	need	to	







development	 agenda	 that	 began	 on	 1	 January	 2016.	 By	 placing	 their	 emphasis	 on	 the	

























































Quantitative	 analytical	 tools	 such	 as	 mathematical	 modelling	 can	 play	 an	 important	 role	 in	
informing	the	End	TB	Strategy,	evaluating	the	impact	of	novel	poverty-reduction	interventions	
nested	in	its	vision	(including	in	combination	with	existing	biomedical	tools),	and	exploring	the	
contribution	 of	 socioeconomic	 drivers	 to	 the	 epidemic.	 However,	 to	 do	 so,	 TB	 models	 will	
inevitably	need	to	expand	their	focus	beyond	diagnosis	and	treatment	to	incorporate	SDs,	but	






















































We	 excluded	 systematic	 reviews,	 epidemiological	 studies	 that	 did	 not	 use	 mathematical	
modelling	techniques	and	ecological	analyses	looking	at	SDs	of	TB.	The	search	focused	on	socio-
economic	 factors	 (i.e.,	 the	 intervention	 or	 exposure	 involving	 a	 socio-economic	 factor),	 and	
excluded	studies	focusing	only	on	diabetes	mellitus	(DM),	the	human	immunodeficiency	virus	










































Socio-economic	 factors	 investigated.	 The	 study	 by	 Reeves	 et	 al.	 (10)	was	 the	 only	 one	 that	
looked	at	the	impact	of	distal	determinants	(i.e.,	government	expenditure	per	capita	on	public	
health	services,	gross	domestic	product	(GDP)	and	cumulative	decline	in	GDP,	as	a	measure	of	
the	 severity	 of	 an	 economic	 recession	 on	 TB	 control.	 	 The	 remainder	modelled	 proximal	 TB	
determinants:	 four	 focused	on	nutritional	status	 (body	mass	 index	[BMI]	and	undernutrition)	
(11-14),	one	on	wealth	(15),	one	on	smoking	and	indoor	air	pollution	(16),	and	one	on	nutritional	
status,	overcrowding	and	socio-economic	status	(17).	All	studies	looked	at	one	factor	at	a	time,	











Transmission	 models	 employed	 standard	 SLIR	 (“Susceptible-Latent-Infectious-Recovered”)	


























(16).	 The	 studies	 that	 focused	 on	 nutritional	 status	 (proximal	 factor)	 found	 that	 reducing	
undernutrition	would	substantially	reduce	TB	incidence.	Andrews	et	al.	showed	that	preferential	
targeting	of	the	poor	can	benefit	TB	control	(wealth	as	proximal	factor)	(15).	From	the	analysis	
of	 reproduction	 numbers	 for	 the	 poor	 and	 rich	 communities,	 Bhunu	 et	 al.	 found	 that	
overcrowding,	poor	nutrition,	 lower	 socioeconomic	 status	 (proximal	 factors)	and	 reduced	TB	
treatment	uptake	worsened	TB	transmission	(17).	Finally,	the	study	by	Dye	et	al.	concluded	that	






























of	 TB	 in	 a	 population.	 Figure	 2	 provides	 a	 conceptual	 framework	 that	 outlines	 how	
distal/structural	 determinants	 (such	 as	 macro-economic	 policies),	 work	 through	 a	 potential	
array	of	more	proximal	determinants	(e.g.,	crowding	and	nutrition),	which	 in	turn	affects	the	
dynamics	of	a	standard	mechanistic	TB	model	at	multiple	points	(18,	19),	such	as	the	intensity	






This	 framework	 provides	 an	 example	 of	 the	 complexity	 when	 considering	 SDs	 in	 TB	 models,	 and	 it	
illustrates	 the	 complicate	 cascade	 of	 parameters	 from	 distal	 to	 downstream	 determinants	 affecting	






























































































of	 transmission,	 e.g.,	 social	 mixing	 or	 crowding	 in	 households,	 but	 also	 parameters	 guiding	
progression	to	disease	after	infection,	which	can	be	affected,	for	example,	by	nutritional	status.	
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reasons,	 requires	 an	 understanding	 of	 their	 interactions,	 and	 further	 increases	 the	 level	 of	
knowledge	required.	Finally,	separating	out	composite	phenomenological	quantities	into	their	



























require	 collaborations	 from	 different	 disciplines,	 including	 social	 scientists,	 epidemiologists,	
economists,	 policymakers	 as	 well	 as	 mathematical	 modellers	 (11).	 While	 recognising	 the	
importance	 of	 such	 projects	 but	 at	 the	 same	 time	 the	 struggle	 to	 identify	 suitable	 funding	
opportunities	 for	 such	 cross-disciplinary	 collaborative	 work,	 the	 TB	 Modelling	 and	 Analysis	
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Even	when	 tuberculosis	 (TB)	 care	 is	 free,	 the	 economic	 burden	 of	 illness	 due	 to	 TB	 can	 be	
devastating,	due	 to	 the	 costs	of	 seeking	and	 staying	 in	 care	 for	 the	 six	months	 to	 two	years	
necessary	for	full	treatment	for	TB	or	multidrug-resistant	TB.		Such	costs	can	create	access	and	
adherence	barriers	that	can	affect	health	outcomes	and	increase	risk	of	disease	transmission.	
These	 costs	 can	also	 contribute	 to	 the	economic	burden	of	households.	 In	 low-	and	middle-
income	countries,	TB	patients	face	costs	that	on	average	amount	to	half	their	annual	income.	
	
One	 of	 the	 three	 targets	 for	 the	 End	 TB	 Strategy	 (2016-2020)	 is	 that	 no	 TB	 patient	 or	 their	
household	should	face	catastrophic	costs	due	to	TB,	and	this	target	should	be	achieved	by	2020.	






































and	 lost	 earnings.	 Therefore,	 both	 health	 financing	 and	 delivery	 models,	 as	 well	 as	 social	






(UHC)	 because	 TB	 cannot	 be	 eliminated	 without	 addressing	 the	 barriers	 to	 uptake	 and	
completion	of	needed	 treatment,	 an	 important	aspect	of	 service	 coverage.	 The	 share	of	 the	
population	incurring	“catastrophic	expenditures”	(expenditures	beyond	a	defined	threshold	of	
a	household’s	capacity	to	pay)	is	one	measure	of	financial	protection	that	is	commonly	used	as	
an	 indicator	of	progress	 towards	UHC	 (2)	 (5).	 The	TB-specific	 indicator	of	 “catastrophic	 total	
costs”	is	different	from	the	population-based	indicator	of	“catastrophic	expenditures”	because	
it	incorporates	both	direct	medical	payments	for	treatment,	direct	non-medical	payments	(such	






Reducing	 direct	 and	 indirect	 costs	 related	 to	 TB	 care	 will	 contribute	 to	 improvements	 in	




the	 health	 financing	 system	 alone	 are	 unlikely	 to	 be	 sufficient	 to	 enable	 the	 diagnosed	 TB-
affected	population	to	overcome	fully	the	barriers	to	successful	completion	of	treatment.	Action	
on	the	demand-side	is	essential,	such	as	e.g.	extension	of	certain	social	protection	mechanisms	







Countries	 are	 recommended	 to	 assess	 the	 composition	 and	 magnitude	 of	 these	 direct	 and	












Findings	 from	this	study	 (which	was	conducted	 in	conjunction	with	Dodowa	Health	Research	
Centre)	 were	 instrumental	 in	 including	 pro-poor	 strategies	 in	 the	 delivery	 of	 TB	 care	
interventions.		
	
In	 2013,	 Ghana	 undertook	 a	 national	 TB	 prevalence	 survey	 which	 showed	 a	 generalised	
epidemic	that	is	four	times	higher	than	previously	estimated	(7).		While	this	survey	has	allowed	
more	 precise	 prevalence	 estimates,	 the	 catastrophic	 costs	 indicator	 is	 new	 and	 as	 such	 it	
requires	urgent	assessment	to	establish	baseline	data	and	estimate	the	contribution	of	costs	to	
the	TB	patient	and	to	TB	control	overall,	thereby	enabling	the	Government	to	address	demand-
side	 cost	 barriers,	which	may	be	done	 through	 a	 range	of	 interventions	 including	 improving	





NTP	during	 the	 implementation	and	 re-programming	of	 the	Global	 Fund	TB	grant	under	 the	




















their	 households)	 in	 the	 country	 who	 incur	 direct	 and	 indirect	 costs	 beyond	 a	 defined	
threshold	of	their	annual	income.		
		
3. To	determine	the	correlation	between	 facing	costs	above	different	 thresholds	of	annual	
household	income	and	the	borrowing	or	selling	assets	to	finance	health	care	expenditure	






1. To	 determine	 the	 association	 between	 costs	 incurred	 by	 TB	 patients	 and	 TB	 treatment	
outcomes	amongst	patients	included	in	the	survey.	
	
Rationale:	 In	 Ghana,	 despite	 progress	 over	 the	 last	 decade,	 the	 prevalence	 of	 adverse	
treatment	 outcomes	 remains	 unacceptably	 high.	 We	 hypothesise	 that	 TB	 patients	
experiencing	 catastrophic	 health	 expenditure	 have	 less	 favourable	 treatment	 outcomes	







Rationale:	 Ghana	 is	 rolling	 out	 an	 intensified	 case	 finding	 strategy	 at	 health	 centres	
nationwide.	We	hypothesise	that	intensified	case	finding	may	reduce	patient	costs	related	












adherence	 based	 on	 baseline	 experience	 and	 to	 enable	 reporting	 on	 the	 2020	 End	 TB	

















Each	patient	will	be	 interviewed	once	 and	will	 report	on	expenditures	 retrospectively.	 Some	
patients	will	be	interviewed	during	the	intensive	treatment	phase	and	others	in	the	continuation	
treatment	phase,	with	expenditure	and	time	loss	data	collected	for	that	particular	phase	only.	




































phase.	 For	new	patients	who	are	 interviewed	 in	 the	 continuation	phase,	 information	will	 be	
































































The	 calculation	 of	 the	 required	 sample	 size	 for	 the	 survey	 was	 based	 on	 the	 following	
assumptions:	
	
1. We	hypothesised	 that	 the	 true	proportion	of	households	experiencing	 catastrophic	 total	























30%	 43	 26	 22	 633	
40%	 49	 29	 25	 721	
50%	 50	 30	 25	 750	
	
	
In	 total,	 twenty-five	 clusters	 were	 selected	 through	 multi-stage	 cluster	 sampling	 among	 all	






















Finally,	 the	 survey	 team	 will	 conduct	 follow	 up	 conversations	 with	 clinic	 staff	 to	 retrieve	






























will	 allow	 individuals	 to	 ask	 questions	 for	 clarification.	 After	 ensuring	 that	 the	 subject	 has	




Patients	 will	 be	 compensated	 with	 a	 pastry/sandwich	 and	 drink	 for	 the	 time,	 travel	 or	
inconvenience	 allocated	 during	 the	 interview.	 Section	 4.6	 provides	 further	 details	 about	 the	
place	of	interview	and	time	required.	
	








a	 unique	 identification	 number	 which	 will	 be	 used	 in	 all	 stages	 of	 data	 collection	 and	
management.	Data	will	 be	 stored	on	encrypted	 servers	and	datasets	will	 be	anonymised	 for	
analysis.	 During	 the	 data	 collection	 phase	 we	 will	 ensure	 confidentiality	 by	 conducting	
interviews	 in	private	 spaces.	We	will	 also	 ensure	 that	only	 the	 study	 team	will	 use	 the	data	
collection	tablets	and	that	these	will	be	stored	in	locked	cupboards	overnight	when	not	in	use.	







































During	 the	 training,	 data	 collectors	 will	 practice	 the	 questionnaire	 on	 each	 other	 and	 in	













6. Be	 familiar	 with	 the	 electronic	 version	 of	 the	 questionnaire	 and	 the	 Android	 tablets	
employed	for	data	collection.	
7. Convey	questions	 in	 the	order	 in	which	 they	are	written	on	 the	questionnaire,	using	 the	
same	wording	 (using	 the	 local	 language)	 as	on	 the	questionnaire.	 It	may	be	 that	 certain	






























The	 survey	 questionnaire,	 data	 entry	 screens	 (electronic	 version	 of	 survey	 questionnaire),	
transfer	of	data	and	feedback	loops,	will	be	tested	during	interviewer	training	and	the	pilot	to	





The	 interview	will	 take	 place	 in	 a	 separate	 space/room	where	 the	 interview	 can	 take	 place	





number	 of	modules	 to	 be	 used).	 	 Prior	 to	 the	 interview,	 the	 interviewer	will	 be	 required	 to	
complete	 some	 questions	 by	 checking	 patient	 records,	 which	 will	 take	 approximately	 15	









The	 study	 will	 employ	 an	 electronic	 survey	 system	 that	 has	 been	 set	 up	 in	 the	WHO	 Data	
Coordination	Platform	(DCP)	for	secure	management	of	electronic	forms	and	data	in	real-time	





Android	 application.	 	 Interviewers	will	 use	Android	 tablets	 during	 the	 interviews	 and	will	 be	
required	to	periodically	connect	to	the	internet	to	upload	the	completed	patient	questionnaires.	
	













PIN	 ##	 ###	 ###	 ######	
	
	







data	 collection	 so	 that	 surveyed	 individuals	 can	 still	 be	 approached	 to	 check	 any	 errors	 or	
discrepancies.		Each	survey	team	will	be	responsible	for	transferring	all	paper-based	documents	
(consent	forms)	to	the	DMU	where	they	will	be	stored	in	folders	in	a	secured	and	safe	storage	












Descriptive,	 univariate	 and	 multivariable	 analyses	 will	 be	 performed	 to	 determine	 the	
magnitude	 and	main	 drivers	 of	 patient	 costs	 in	Ghana	 (Objective	 1).	 	 Further	 disaggregated	
analysis	will	be	conducted	to	understand	which	types	of	costs	are	most	important	in	Ghana.	This	
will	involve,	for	example,	disaggregating	out-of-pocket	payments	into	payments	for	medicines,	
tests,	 consultation	 fees	 etc.,	 and	 disaggregating	 out-of-pocket	 non-medical	 payments	 into	
payments	 for	 travel,	 food,	 etc.	Moreover,	 if	 patient	 numbers	will	 allow,	 associations	will	 be	
analysed	between	costs	and	patient	characteristics	(socioeconomic	position,	sex,	occupation),	
place	and	model	of	care	(ambulatory,	self-administered,	hospital-based	etc.),	type	of	provider	























The	 second	 approach	will	 calculate	 the	 percentage	 of	 households	 experiencing	 any	 level	 of	
dissaving	(such	as	taking	a	loan	or	selling	property	or	livestock)	to	face	health	costs	associated	




context	 of	 the	 household	 of	 the	 patient.	 Therefore,	 the	 analysis	 will	 take	 into	 account	 the	






Patients	 will	 be	 interviewed	 in	 different	 phases	 of	 the	 illness	 episode,	 and	 reporting	 on	
retrospective	expenditures	and	time	 loss.	As	data	will	be	collected	 for	 the	particular	episode	
phase	the	patient	is	in	cost	will	be	predominantly	estimated	for	other	phases	and	estimation	will	
be	done	using	costs	calculated	for	similar	patients	 interviewed	 in	the	other	phases	of	 illness,	
matched	by	type	of	TB	and	facility.	For	example,	a	new	drug-susceptible	patient	 interviewed	
during	their	continuation	phase	will	not	report	all	costs	they	incurred	during	the	intensive	phase.	







1. Which	 factors	 are	 most	 significantly	 associated	 with	 an	 individual	 TB	 patient	
experiencing	catastrophic	total	cost	and	TB	treatment	outcomes	(Objective	4);	
	


















































My	name	 is	 (name	of	 interviewer).	 I	 am	working	 for	 the	Dodowa	Health	Research	Centre	 in	

























































ask	 questions	 about	 it	 and	 any	 questions	 I	 have	 been	 asked	 have	 been	 answered	 to	 my	
satisfaction.	I	consent	voluntarily	to	be	a	participant	in	this	study.	
	
Print	Name	of	Participant	 	 				 	__________________________________
	 	 	 	
Signature/Thumb	print	of	Participant	 	 	__________________________________	
	
Date		 	 	 	 	 							 	_______________________________	





individual	 has	 had	 the	 opportunity	 to	 ask	 questions.	 I	 confirm	 that	 the	 individual	 has	 given	
consent	freely.		
 
Print	name	of	witness	 	 	 	 _______________________________	
Signature/Thumb	print	of	witness					 	 _______________________________	
Date	 	 	 	 	 	 _______________________________	


















Date	 	 	 	 	 	 	 __________________________		





































If	 you	 accept	 to	 take	 part	 in	 this	 research	 project,	 your	 parents/guardian	 will	 be	 asked	 to	












































Date:	 	 	 	 ____________________	



















Date	 	 	 	 	 	 	 ___________________________
















My	name	 is	 (name	of	 interviewer).	 I	 am	working	 for	 the	Dodowa	Health	Research	Centre	 in	








Your	 child	 is	 being	 invited	 to	 take	 part	 in	 this	 research	 project	 because	 he/she	 is	 currently	






















































Print	Name	of	Parent/Guardian		 	 		 ___________________________	
	 	 	 	
Signature/Thumb	print	of	Parent/Guardian	 		 	___________________________	
	
Date		 	 	 	 				 	 	 ___________________________	










Print	name	of	witness	 	 	 ________________________						
Signature/	Thumb	print	of	witness	 ________________________	
Date	 	 	 	 	 ________________________	





I	have	accurately	 read	out	 the	 information	sheet	 to	 the	potential	participant,	and	 to	
the	 best	 of	 my	 ability	 made	 sure	 that	 the	 participant	 understands	 the	 purpose,	
procedures	 (i.e.	 interview	 that	 will	 last	 60-90	 minute,	 measurements	 of	 height	 and	
weight),	potential	risks	and	benefits	of	the	study.	
	













































M	 J	 J	 A	 S	 O	 N	 D	 J	 F	 M	
Survey	 	
Adaptation	of	the	generic	protocol	
and	questionnaire	 	 	 	 	 	 	 	 	
	 	 	
Ethics	Committee	Submission	 		 		 		 		 		 		 		 		 	 	 	
SOP	Writing	 		 		 		 		 		 		 		 		 	 	 	
Translation	of	questionnaire	into	
local	languages	 		 		 		 		 		 		 		 		
	 	 	
Electronic	survey	adaptation	 		 		 		 		 		 		 		 		 	 	 	
Training	for	survey	team	 		 		 		 		 		 		 		 		 	 	 	
Data	collection	 		 		 		 		 		 		 		 		 	 	 	
Follow-up	of	treatment	outcomes	 	 	 	 	 	 	 	 	 	 	 	
Analyses	plans	 		 		 		 		 		 		 		 		 	 	 	
Data	Cleaning	/	Analysis	 		 		 		 		 		 		 		 		 	 	 	

































































9. Sex							 1.	Male	[_____]	2.	Female	[_____]	 Circle	appropriate	number	or	fill	answer	
on	the	answer	line	
Sex	


















































































































































































































































































































Do	not	fill	 Filled	□	 Filled	□	 	
1	 2	 First	line,	new	case,	interviewed	in	the	continuation	
treatment	phase	
Do	not	fill	 Do	not	fill	 Filled	□	 	
2-4	 1	
or	2	
First	line,	relapse	or	retreatment	 Filled	□	 Do	not	fill	 Filled	□	 	
	






phase	 Do	not	fill	 Do	not	fill	 Filled	□	
	
















27. Which	year	were	you	treated	for	the	first	time	for	TB?	 [_________]	 	 Pretrt_1	
















































































Second	treatment		 	 	 	
32. Which	year	were	you	treated	for	the	second	time	for	TB?	 [_________]	 	 Pretrt_2	












































37. Which	year	were	you	treated	for	the	third	time	for	TB?	 [_________]	 	 Pretrt_3	



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3. 	 If	patients	receive	cash,	what	is	the	amount?	 [___________]	
4. 	 If	patients	receive	food,	what	type	(and	quantity)	of	food	do	they	receive	
[___________];	[_______]	gr	
[___________];	[_______]	gr	
5. 	 If	patients	receive	vouchers,	what	is	their	value?	
[___________]	
6. 	 How	often	patient	receive	the	enabler	package?	
1. Weekly	
2. Monthly	
3. Other	[___________]	
7. 	 Where	patients	collect	their	cash/food/vouchers?	
1. Clinic	
2. From	community	workers	
3. Other	
Intensified	case	finding	(ICF)	
8.	 Is	the	facility	in	a	district	that	is	prioritised	for	ICF?	 	
9.	 Is	the	symptoms-based	screening	tool	available	in	the	health	facility?	
Need	to	physically	see	the	form	
	
10.	 Is	the	symptoms-based	screening	tool	being	used?	 Check	to	see	if	names	appear	on	the	form	
11.	
If	the	health	facility	is	not	using	the	tool	or	if	the	tool	is	not	present,	
then	is	there	another	method	that	the	healthcare	staff	are	
implementing	and	logging	intensified	screening?	
	
	
12.	
Is	there	clear	assignment	to	one	or	more	people	who	are	given	the	
role	of	initial	screening	(e.g.	asking	attendants	for	cough)?	
	
	
	
 216	
13.	
If	so,	what	is	the	number	of	individuals	responsible	for	managing	the	
form?	
	
	
14.	 Have	these	individuals	received	official	training	on	the	use	of	the	tool?	
	
15	 What	is	the	number	of	health	care	staff	trained	on	using	the	tool?		
Will	need	to	make	adjustments	based	on	
population/catchment	area,	e.g.	population	covered	by	
BMU?	
16.	
How	is	the	tool	being	implemented,	i.e.	how	to	attendants	get	onto	
the	screening	form?	(policy	is	to	ask	all	clinic	attendants	for	cough)	
1. All	attendants	are	asked	if	they	have	a	cough	upon	entry.	If	they	
have	a	cough,	they	are	marked	on	the	screening	form.		
2. A	healthcare	worker	goes	around	the	waiting	room	asking	
attendants	if	they	have	a	cough.	If	they	have	a	cough,	they	are	
marked	on	the	screening	form.		
3. Healthcare	workers	mark	the	individual	down	on	the	screening	
form	when	a	cough	is	heard.		
4. When	an	attendant	mentions	they	have	a	cough	to	the	
healthcare	professional,	then	they	are	marked	down	on	the	
screening	form.	
5. Other:	_________________________	
	
17.	
What	is	the	duration	of	cough	needed	for	an	individual	to	be	marked	
on	the	screening	form?	
1. Cough	of	any	duration	
2. Cough	of	1	week	
3. Cough	of	2	weeks	
4. Other:	__________________________	
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Appendix	4:	LSHTM	Ethics	approval	
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Appendix	5:	Approval	from	the	Ghana	Health	Service	Ethics	Review	Committee	
